n another effort to curb the worsening deficit in the state health insurance, the government has attempted to remove more cancer medicines from its coverage, which may put the lives of patients on the line.
The Health Ministry has issued a new ministerial decree on the national formulary that excludes bevacizumab, a medication used mostly for targeted chemotherapy to treat metastatic colorectal cancer, from the list of medicines covered under the National Health Insurance (JKN) scheme.
The new regulation that will be effective on March 1 also stops the use of cetuximab, also used for colorectal cancer. The new formulary stipulates that it can only be used to treat Squamous cell carcinoma, also known as head and neck cancer.
Husain Nurisman, 45, who survived metastatic colorectal cancer last year thanks to the combination of both medicines, said he was now more afraid if his cancer would reoccur.
Although Husain is covered by the insurance scheme under the Health Care and Social Security Agency (BPJS Kesehatan), he relied on financial assistance from his office that offered to cover all of his expenses.
Husain said his office had to spend Rp 60 million (US$4,300) for each targeted therapy session. Last year, he underwent 10 treatments in five months and his office covered the Rp 600 million bill.
“I don’t know what I will do if one day the cancer returns when I have retired. If at that time these two medicines are not covered by the JKN, I think I will ask the doctors to euthanize me instead. My family will lose everything if they have to pay and I don’t want to see them suffer because of me,” he said.
Share your experiences, suggestions, and any issues you've encountered on The Jakarta Post. We're here to listen.
Thank you for sharing your thoughts. We appreciate your feedback.